368 related articles for article (PubMed ID: 30352799)
1. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
Ghonime MG; Cassady KA
Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
[TBL] [Abstract][Full Text] [Related]
2. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
Mahller YY; Rangwala F; Ratner N; Cripe TP
Pediatr Blood Cancer; 2006 Jun; 46(7):745-54. PubMed ID: 16124003
[TBL] [Abstract][Full Text] [Related]
3. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
[TBL] [Abstract][Full Text] [Related]
4. STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells.
Jackson JD; Markert JM; Li L; Carroll SL; Cassady KA
Mol Cancer Res; 2016 May; 14(5):482-92. PubMed ID: 26883073
[TBL] [Abstract][Full Text] [Related]
5. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.
Mahller YY; Vaikunth SS; Currier MA; Miller SJ; Ripberger MC; Hsu YH; Mehrian-Shai R; Collins MH; Crombleholme TM; Ratner N; Cripe TP
Mol Ther; 2007 Feb; 15(2):279-86. PubMed ID: 17235305
[TBL] [Abstract][Full Text] [Related]
7. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.
Lee TJ; Nair M; Banasavadi-Siddegowda Y; Liu J; Nallanagulagari T; Jaime-Ramirez AC; Guo JY; Quadri H; Zhang J; Bockhorst KH; Aghi MK; Carbonell WS; Kaur B; Yoo JY
Mol Cancer Ther; 2019 Jun; 18(6):1127-1136. PubMed ID: 30926634
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.
Yoo JY; Hurwitz BS; Bolyard C; Yu JG; Zhang J; Selvendiran K; Rath KS; He S; Bailey Z; Eaves D; Cripe TP; Parris DS; Caligiuri MA; Yu J; Old M; Kaur B
Clin Cancer Res; 2014 Jul; 20(14):3787-98. PubMed ID: 24815720
[TBL] [Abstract][Full Text] [Related]
9. STING Restricts oHSV Replication and Spread in Resistant MPNSTs but Is Dispensable for Basal IFN-Stimulated Gene Upregulation.
Lee JM; Ghonime MG; Cassady KA
Mol Ther Oncolytics; 2019 Dec; 15():91-100. PubMed ID: 31650029
[TBL] [Abstract][Full Text] [Related]
10. Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.
Jackson JD; McMorris AM; Roth JC; Coleman JM; Whitley RJ; Gillespie GY; Carroll SL; Markert JM; Cassady KA
Gene Ther; 2014 Nov; 21(11):984-90. PubMed ID: 25119379
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
Alayo QA; Ito H; Passaro C; Zdioruk M; Mahmoud AB; Grauwet K; Zhang X; Lawler SE; Reardon DA; Goins WF; Fernandez S; Chiocca EA; Nakashima H
Sci Rep; 2020 Mar; 10(1):5095. PubMed ID: 32198420
[TBL] [Abstract][Full Text] [Related]
13. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
Crespo-Rodriguez E; Bergerhoff K; Bozhanova G; Foo S; Patin EC; Whittock H; Buus R; Haider S; Muirhead G; Thway K; Newbold K; Coffin RS; Vile RG; Kim D; McLaughlin M; Melcher AA; Harrington KJ; Pedersen M
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759235
[TBL] [Abstract][Full Text] [Related]
14. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.
Antoszczyk S; Spyra M; Mautner VF; Kurtz A; Stemmer-Rachamimov AO; Martuza RL; Rabkin SD
Neuro Oncol; 2014 Aug; 16(8):1057-66. PubMed ID: 24470552
[TBL] [Abstract][Full Text] [Related]
15. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication.
Mahller YY; Sakthivel B; Baird WH; Aronow BJ; Hsu YH; Cripe TP; Mehrian-Shai R
Cancer Gene Ther; 2008 Nov; 15(11):733-41. PubMed ID: 18551144
[TBL] [Abstract][Full Text] [Related]
17. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
[No Abstract] [Full Text] [Related]
18. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
19. Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft.
Liu S; Zhang J; Fang S; Su X; Zhang Q; Zhu G; Zhu L; Zhao M; Liu F
Cancer Lett; 2020 Dec; 495():123-134. PubMed ID: 32946963
[TBL] [Abstract][Full Text] [Related]
20. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]